Precision medicine is becoming the norm in life sciences research but obstacles such as limited reimbursement for tests are hindering progress, according to a new survey.
Bristol-Myers Squibb has scored a victory against arch-rivals Merck, with a new much more convenient dosing schedule for Opdivo which could help it keep ahead in the sales race.
NICE has recommended Merck KGaA and Pfizer’s Bavencio in previously treated metastatic Merkel Cell Carcinoma, a rare and aggressive form of skin cancer.
Grail, the US-based cancer detection startup backed by billionaires Jeff Bezos and Bill Gates is reportedly mulling a launch on the Hong Kong stock exchange.
